Praglandia s.r.o.

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)4 trials
• Migraine2 trials
• Depression1 trial

Phase

• Phase 36 trials
• Phase 21 trial

Status

• Completed7 trials

Lead sponsor

• AbbVie2 trials
• Amgen Inc.2 trials
• Anaptysbio Inc.1 trial
• Janssen Cilag International1 trial
• Sanofi1 trial

Closed trials

• Completed

  Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis

  2023-503522-40-01· Phase 2· Anaptysbio Inc.· Source

• Completed

  Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

  NCT06241313· Phase 3· AbbVie· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

  NCT06224348· Phase 3· Sanofi· Source

• Completed

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· Phase 3· Amgen Inc.· Source

• Completed

  Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine

  NCT05748483· Phase 3· AbbVie· Source

• Completed

  A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression.

  2023-508163-74-00· Phase 3· Janssen Cilag International· Source

• Completed

  A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon)

  2022-501538-44-00· Phase 3· Amgen Inc.· Source